NCT07168655View on ClinicalTrials.gov

Mavacamten in Obstructive Hypertrophic Cardiomyopathy

CompletedOBSERVATIONAL
Enrollment

163

Participants

Timeline

Start Date

February 21, 2023

Primary Completion Date

March 31, 2023

Study Completion Date

March 25, 2025

Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
DRUG

Mavacamten

According to the product label

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY